Crescendo Biologics presents preclinical data on lead clinical candidate CB307 and unveils its first ‘2 in 1’ immune cell engager CB699 at AACR 2024 Crescendo Biologics presents preclinical data on lead clinical candidate CB307 and unveils its first ‘2 in 1’ immune cell engager CB699 at AACR 2024 Preclinical data demonstrate strong rationale for...

Crescendo Biologics to present at the 2024 AACR Annual Meeting Crescendo Biologics to present at the 2024 AACR Annual Meeting Cambridge, UK, 6 March 2024 – Crescendo Biologics Ltd (Crescendo), a clinical stage, immuno-oncology company developing novel, targeted...

BioNTech und Crescendo Biologics geben globale Kollaboration zur Entwicklung multispezifischer Präzisionsimmuntherapien bekannt Die Zusammenarbeit kombiniert BioNTechs unternehmenseigene multimodulare Immuntherapie-Expertise mit Crescendos proprietärer Humabody® VH Plattform zur Entwicklung von Präzisionsimmuntherapien,...

BioNTech and Crescendo Biologics Announce Global Collaboration to Develop Multi-specific Precision Immunotherapies Collaboration leverages BioNTech’s proprietary multimodal immunotherapy expertise with Crescendo’s proprietary Humabody® VH platform to develop precision immunotherapies, including mRNA-based...